Corresponding Author: Anat Loewenstein, MD, MHA, Tel Aviv Medical Center, Tel Aviv University, 6 Weizmann St, Tel Aviv 64239, Israel (anatl@tlvmc.gov.il).
Published Online: July 18, 2019. doi:10.1001/jamaophthalmol.2019.2137
Conflict of Interest Disclosures: Dr Loewenstein reports grants and personal fees from Allergan plc and Bayer Healthcare AG; personal fees from Alcon, Alimera, Beyeonics, ForSight Labs, and NotalVision; and grants from Novartis and Sensor, all outside of the submitted work. Dr Korobelnik reports personal fees and nonfinancial support from Bayer Healthcare AG during the conduct of this study and personal fees from Alcon, Allergan plc, Alimera, Bayer, Chengdu Kanghong Pharmaceuticals, Novartis, Roche, Thea, and Zeiss outside of the submitted work. Dr Okada reports personal fees from Bayer Healthcare Pharmaceuticals during the conduct of this study; personal fees from AbbVie, Astellas Japan, Daiichi-Sankyo, and Senju Pharmaceutical, outside the submitted work; grants and personal fees from Bayer Yakuhin Ltd, Novartis Pharma Japan, Santen Pharmaceutical Co Ltd, and Alcon Pharma KK, during the conduct of this study; and grants and personal fees from Mitsubishi-Tanabe Pharma, outside the submitted work.
Additional Contributions: We thank the patient for granting permission to publish this information and Patricia Udaondo, MBBS, Hospital Universitario y Politécnico La Fe, for providing the case study (uncompensated). Medical writing assistance was provided by Katie L. Beski, PhD, Complete HealthVizion Ltd, who was funded by Bayer Consumer Care AG.
1.Gross
JG, Glassman
AR, Liu
D,
et al; Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.
JAMA Ophthalmol. 2018;136(10):1138-1148.
PubMedGoogle ScholarCrossref 2.Sivaprasad
S, Prevost
AT, Vasconcelos
JC,
et al; CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Lancet. 2017;389(10085):2193-2203.
PubMedGoogle ScholarCrossref 3.Gross
JG, Glassman
AR, Jampol
LM,
et al; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.
JAMA. 2015;314(20):2137-2146.
PubMedGoogle ScholarCrossref 4.Schmidt-Erfurth
U, Garcia-Arumi
J, Bandello
F,
et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA).
Ophthalmologica. 2017;237(4):185-222.
PubMedGoogle ScholarCrossref 5.Wells
JA, Glassman
AR, Ayala
AR,
et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
N Engl J Med. 2015;372(13):1193-1203.
PubMedGoogle ScholarCrossref 6.Bressler
SB, Liu
D, Glassman
AR,
et al; Diabetic Retinopathy Clinical Research Network. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab.
JAMA Ophthalmol. 2017;135(6):558-568.
PubMedGoogle ScholarCrossref 7.Stewart
MW. Treatment of diabetic retinopathy: recent advances and unresolved challenges.
World J Diabetes. 2016;7(16):333-341.
PubMedGoogle ScholarCrossref 8.Brown
DM, Schmidt-Erfurth
U, Do
DV,
et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID Studies.
Ophthalmology. 2015;122(10):2044-2052.
PubMedGoogle ScholarCrossref